RhumbLine Advisers
ARQT icon

RhumbLine Advisers’s Arcutis Biotherapeutics ARQT Stock Holding History

RhumbLine Advisers’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.47M Buy
170,542
+9,411
+6% +$219K ﹤0.01% 1534
2026
Q1 		$3.8M Sell
161,131
-271
-0.2% -$6.92K ﹤0.01% 1534
2025
Q4 		$4.69M Sell
161,402
-21,727
-12% -$556K ﹤0.01% 1434
2025
Q3 		$3.45M Sell
183,129
-2,970
-2% -$46.8K ﹤0.01% 1614
2025
Q2 		$2.61M Buy
186,099
+5,025
+3% +$70.4K ﹤0.01% 1744
2025
Q1 		$2.83M Buy
181,074
+13,022
+8% +$183K ﹤0.01% 1638
2024
Q4 		$2.34M Buy
168,052
+4,598
+3% +$50.4K ﹤0.01% 1802
2024
Q3 		$1.52M Sell
163,454
-3,835
-2% -$37.8K ﹤0.01% 2046
2024
Q2 		$1.56M Buy
167,289
+41,956
+33% +$379K ﹤0.01% 2017
2024
Q1 		$1.24M Buy
125,333
+18,402
+17% +$137K ﹤0.01% 2132
2023
Q4 		$345K Buy
106,931
+27,501
+35% +$74.8K ﹤0.01% 2893
2023
Q3 		$422K Buy
79,430
+878
+1% +$7.47K ﹤0.01% 2710
2023
Q2 		$749K Buy
78,552
+24,386
+45% +$271K ﹤0.01% 2452
2023
Q1 		$596K Buy
54,166
+789
+1% +$11.4K ﹤0.01% 2369
2022
Q4 		$790K Buy
53,377
+8,703
+19% +$152K ﹤0.01% 2254
2022
Q3 		$854K Buy
44,674
+3,329
+8% +$75.4K ﹤0.01% 2229
2022
Q2 		$881K Buy
41,345
+6,005
+17% +$123K ﹤0.01% 2205
2022
Q1 		$681K Sell
35,340
-262
-0.7% -$4.43K ﹤0.01% 2280
2021
Q4 		$738K Buy
35,602
+18
+0.1% +$358 ﹤0.01% 2338
2021
Q3 		$850K Buy
35,584
+1,300
+4% +$29.6K ﹤0.01% 2300
2021
Q2 		$936K Buy
34,284
+14,151
+70% +$399K ﹤0.01% 2274
2021
Q1 		$582K Buy
20,133
+45
+0.2% +$1.41K ﹤0.01% 2417
2020
Q4 		$565K Buy
20,088
+3,113
+18% +$76.3K ﹤0.01% 2394
2020
Q3 		$497K Buy
16,975
+5,944
+54% +$159K ﹤0.01% 2291
2020
Q2 		$334K Buy
11,031
+1,150
+12% +$33.2K ﹤0.01% 2525
2020
Q1 		$294K Buy
+9,881
New +$265K ﹤0.01% 2419

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

RhumbLine Advisers's ARQT Position: Q2 2026 in Review

RhumbLine Advisers increased its Arcutis Biotherapeutics (ARQT) stake by 5.8% in Q2 2026, buying an estimated $219K and bringing the position to 170,542 shares worth $4.47M. The position accounts for ﹤0.01% of the portfolio, ranked #1534.

RhumbLine Advisers first reported a position in ARQT in Q1 2020 and has held it in 26 quarters since. The position peaked at $4.69M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • RhumbLine Advisers held 170,542 shares of Arcutis Biotherapeutics worth $4.47M as of Q2 2026.
  • RhumbLine Advisers bought 9,411 Arcutis Biotherapeutics shares in Q2 2026, an estimated $219K.
  • Arcutis Biotherapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1534 holding.
  • RhumbLine Advisers first reported a position in Arcutis Biotherapeutics in Q1 2020 and has held it in 26 quarters since.
  • RhumbLine Advisers's Arcutis Biotherapeutics position peaked at $4.69M in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.